Biopharma Leaders Unite To Stand With Science LEARN MORE Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 LEARN MORE BioNTech and Pfizer Initiate Rolling Submission to EMA for BNT162b2 LEARN MORE Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations LEARN MORE LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer LEARN MORE RECENT PRESS RELEASES 27/02/2020 - Mylan and Pfizer Finalize Appointments to Viatris Board of Directors 25/02/2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 18/02/2020 - European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) 11/02/2020 - XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC 31/01/2020 - Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab) 28/01/2020 - PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS 23/01/2020 - Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults 23/01/2020 - PFIZER’S GREENSTONE AND DIGITAL MEN’S HEALTH CLINIC ROMAN COLLABORATE TO OFFER PATIENTS REMOTE ACCESS TO THE ONLY FDA-APPROVED AUTHORIZED GENERIC VERSION OF VIAGRA® (SILDENAFIL CITRATE) 06/01/2020 - BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Current page 7
